title: Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.
authors.forename: Jack
authors.initials: J
authors.lastname: Ishak
authors.forename: Filipe
authors.initials: F
authors.lastname: Rodrigues
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001897:Boronic Acids / Q000191:economics / Q000627:therapeutic use; D000069286:Bortezomib; D003362:Cost-Benefit Analysis; D003907:Dexamethasone / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D053208:Kaplan-Meier Estimate; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics*; D011719:Pyrazines / Q000191:economics / Q000627:therapeutic use; D012008:Recurrence; D013548:Sweden; D013792:Thalidomide / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide